Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,636.73
(
-1.18%
)
US TECH 100
23,889.60
(
-1.01%
)
Dow Jones
46,260.81
(
-1.56%
)
Brent Oil
105.79
(
5.11%
)
Bitcoin
71,210.04
(
-3.70%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 134655

Thursday, 04/19/2012 6:49:06 PM

Thursday, April 19, 2012 6:49:06 PM

Post# of 257253
From a manpower standpoint, PFE’s Tofacitinib could be hitting the US market at just the right time. PFE is already scaling back US promotion of Enbrel in advance of AMGN’s re-acquiring the full US and Canadian rights to Enbrel in Oct 2013:

http://online.wsj.com/article/BT-CO-20120418-717671.html

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now